Blueberries Medical secures C$1.05M to fund expansion and operations across Latin America

Blueberries Medical Corp. announced a non-brokered private placement consisting of the sale of 96,064,935 common shares at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000).

The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2025.

It is expected that the Offering will be led by Terraflos Inc., a company with operations throughout Latin America founded and controlled by Facundo Garreton, who serves as the Chairman, CEO, and as a director of Blueberries. The company's objective is to satisfy food and medicine needs in the near future using non-conventional methods, without exploiting natural resources as is common in current methodologies. In addition, Guillermo Rodriguez, a director of the Company, is also expected to participate in the Offering.

Mr. Garreton, through Terraflos, acquired the Common Shares for investment purposes, and he may, depending on the market and other conditions, increase or decrease his beneficial ownership, control or direction over additional securities of the securities or otherwise. Other than as noted above and a right to a board seat for so long as Mr. Garreton holds at least 8% of the outstanding Common Shares on an as-converted basis, Mr. Garreton does not have any plans related to any of the matters in the enumerated list in Item 5.1 of Form 62-103F1.

Mr. Garreton will prepare and file a report containing the information required by Form 62-103F1 - Required Disclosure under the Early Warning Requirements in connection with the matters referred to in this press release.